Form 4: Lineage Cell Therapeutics Director Acquires 75,000 Stock Options
SEC Form 4 Filing
Michael H. Mulroy, a director of Lineage Cell Therapeutics, acquired 75,000 stock options on July 1, 2024, exercisable at $0.9541 per share.
Summary
- Michael H. Mulroy, a director of Lineage Cell Therapeutics, acquired 75,000 stock options on July 1, 2024.
- The options have an exercise price of $0.9541.
- The options will vest and become exercisable on July 1, 2025, contingent upon the director's continued service with the company.
- The options expire on July 1, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. The vesting schedule suggests a commitment to the company.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting of the options is contingent upon the director's continued service with the company, suggesting an expectation of ongoing involvement.
Industry Context
This filing is a routine disclosure related to insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of transaction: Director acquired 75,000 stock options. |
| 07/01/2025 | Vesting date: Stock options vest and become exercisable, subject to continuous service. |
| 07/01/2034 | Expiration date: Stock options expire. |
| 07/03/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.